SCHEMBL1680348

SCHEMBL1680348

COC(=O)c1ccc2[nH]ncc(=O)c2c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.59
ALDH1A1 P00352 3/20 0.59
HSD17B10 Q99714 3/20 0.59
HPGD P15428 2/20 0.59
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
CREBBP Q92793 1/20 0.47
PARP1 P09874 3/20 0.46
CSNK2A1 P68400 1/20 0.46
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
KIF11 P52732 2/20 0.45
ATM Q13315 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
GPR84 Q9NQS5 1/20 0.44
MAPK1 P28482 2/20 0.44
POLB P06746 1/20 0.44
CCNE1 P24864 1/20 0.43
CDK2 P24941 1/20 0.43
CDK3 Q00526 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL348190 0.80 NPC1 (0.58) NPC1RAB9AMEN1KMT2AL3MBTL1
SCHEMBL29643714 0.80 NPC1 (0.58) NPC1RAB9AMEN1KMT2AL3MBTL1
SCHEMBL29643878 0.77 MAOB (0.55) KDM4EALDH1A1HSD17B10NPC1RAB9A
SCHEMBL347171 0.77 MAOB (0.55) KDM4EALDH1A1HSD17B10NPC1RAB9A
SCHEMBL28887308 0.77 MAOB (0.50) NPC1RAB9ACSNK2A1MEN1KMT2A
SCHEMBL22981138 0.77 MAPK1 (0.47) KDM4EALDH1A1HSD17B10HPGDNPC1
SCHEMBL29698443 0.77 MAPK1 (0.47) KDM4EALDH1A1HSD17B10HPGDNPC1
SCHEMBL1501529 0.76 KDM4E (0.55) KDM4EALDH1A1HSD17B10HPGDNPC1
SCHEMBL16929779 0.76 JAK2 (0.58) KDM4EALDH1A1HSD17B10HPGDNPC1
SCHEMBL2177132 0.76 KDM4E (0.62) KDM4EALDH1A1HSD17B10HPGDNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200031811-A1 SUBSTITUTED MONO- AND POLYAZANAPHTHALENE DERIVATIVES AND THEIR USE BASILEA PHARM INT AG (CH) 2020-01-30 US disclosed
US-20180002321-A1 SUBSTITUTED MONO- AND POLYAZANAPHTHALENE DERIVATIVES AND THEIR USE Basilea Pharmaceutica International AG (CH) 2018-01-04 US disclosed
EP-3256217-A1 SUBSTITUTED MONO- AND POLYAZANAPHTHALENE DERIVATIVES AND THEIR USE Basilea Pharmaceutica International AG (CH) 2017-12-20 EP disclosed
WO-2016128465-A1 SUBSTITUTED MONO- AND POLYAZANAPHTHALENE DERIVATIVES AND THEIR USE BASILEA PHARMACEUTICA AG (CH) 2016-08-18 WO disclosed
WO-2016128465-A1 SUBSTITUTED MONO- AND POLYAZANAPHTHALENE DERIVATIVES AND THEIR USE BASILEA PHARMACEUTICA AG (CH) 2016-08-18 WO disclosed
US-20110195999-A1 NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND NAKAMOTO KAZUTAKA 2011-08-11 US disclosed
US-7932272-B2 Antifungal agent containing heterocyclic compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-04-26 US disclosed
US-20090227799-A1 Novel Antimalarial Agent Containing Heterocyclic Compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-09-10 US disclosed
US-20070105943-A1 Novel antifungal agent containing heterocyclic compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2007-05-10 US disclosed
EP-1782811-A1 NOVEL ANTIMALARIA AGENT CONTAINING HETEROCYCLIC COMPOUND Eisai R&D Management Co., Ltd. (JP) 2007-05-09 EP disclosed
EP-1669348-A1 NOVEL ANTIFUNGAL AGENT COMPRISING HETEROCYCLIC COMPOUND Eisai Co., Ltd. (JP) 2006-06-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195999-A1 NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND ERG28, CYP51A1, XPO1 KDM4E 3112/4885ALDH1A1 1677/4885HSD17B10 3209/4885
US-20090227799-A1 Novel Antimalarial Agent Containing Heterocyclic Compound XPO1, THPO, G6PD KDM4E 3022/4885ALDH1A1 1926/4885HSD17B10 3600/4885
US-20070105943-A1 Novel antifungal agent containing heterocyclic compound ERG28, DPM1, CYP51A1 KDM4E 3245/4885ALDH1A1 1459/4885HSD17B10 3346/4885
US-20180002321-A1 SUBSTITUTED MONO- AND POLYAZANAPHTHALENE DERIVATIVES AND THEIR USE CBR3, SCO2, CBR1 KDM4E 3811/4885ALDH1A1 2023/4885HSD17B10 370/4885
US-20200031811-A1 SUBSTITUTED MONO- AND POLYAZANAPHTHALENE DERIVATIVES AND THEIR USE CBR3, SCO2, CBR1 KDM4E 3808/4885ALDH1A1 2016/4885HSD17B10 374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.